The medtronic sphere-360™ pulse field ablation (pfa) catheter, a new paradigm in single-shot ablation, demonstrates impressive results in treating paroxysmal atrial fibrillation

Ehra late-breaking data: results highlight efficacy, safety, and durability of the novel pfa catheter that is fully integrated with affera™ mapping and ablation system dublin and berlin , april 8, 2024 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced positive clinical trial safety and efficacy results for sphere-360™, an investigational single-shot mapping and ablation catheter using pulsed field (pf) energy, for treatment of patients with paroxysmal atrial fibrillation (afib). interim findings from the first-in-human sphere-360 study were presented as a late-breaking clinical trial at the european heart rhythm association (ehra) 2024 annual meeting.
MDT Ratings Summary
MDT Quant Ranking